During the Feasibility assessment mySkin d.o.o. in partnership with ORS Hospital ran in-clinical tests confirming that ScanZ reduces assessment time up to 67% and visit time by up to 44%. The in-clinical test had shown that the device increases the throughput of the clinical with quantified measurements, giving better insight into each lesion changes and enabling physicians to have a consistent diagnostic quality. Post visit, the ScanZ platform introduces an objective element in monitoring lesions between visits.
The conducted (e/tele)-interviews with dermatologists have shown that there is a high demand for the ScanZ device. Prominent acne researchers have been looking or trying to develop such a device since 2005. Now that digital medical devices have become more recently available and popular, ScanZ is an ideal solution for implementation into their clinical staff and patient processes. The key criteria of selecting an appropriate device for the dermatologists was having a simple, easy to use device, that saves times, is affordable, and most importantly quantify acne and skin lesions.
Thanks to the Feasibility study, mySkin has decided to change the strategy by first focusing on the MD device, and then after understanding the clinical use-cases and patient flow, focus on the consumer edition (CE) of ScanZ. It would be the most efficient way to medicallyvalidate and certify the device and test both users experience and to become internationally recognized.
mySkin has achieved the business feasibility objectives defined in the PH1 proposal, by securing 4 hospitals (3 outside Serbia) for the clinical trials, obtaining interests of the EMDDA, conducting the comprehensive and market barriers analysis, as well as preparing the IP and marketing strategy and 5 years financial projection.
